Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for symptomatic congenital cytomegalovirus disease
jRCT2051190075Active, not recruiting
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of valganciclovir in congenital cytomegalovirus infection (cCMV). Primary endpoint: Change in whole blood viral load. Started Feb 2020; status: active, not recruiting.
02
Drugs
valganciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on jRCT2051190075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051190075.